Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotegravir ULA + Rilpivirine ULA in Virologically Suppressed HIV
NCT07650916Phase 3Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jun 2026
- Primary completion
- Sep 2029
- Countries
- 10
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Jun 2026; status: recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07650916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650916.